Assay Service request for assessing select required DMPK properties of potential therapeutic compounds generated in SMC

The National Institutes of Health Office of the Director is seeking a Firm-Fixed-Price contract under solicitation 75N98026Q01251 for orthogonal Assay Development and Laboratory Testing Services. The primary objective is to assess the translational potential of novel molecular entities for treating metabolic and alcohol-associated diseases. The scope of work includes grouped DMPK assays and pharmacokinetic studies utilizing C57BL6 mice to provide experimental validation of in silico data, which is critical for informing structure-activity relationship optimization. The period of performance is one year from the date of award, and the total contract value is not expected to exceed the simplified acquisition threshold of 350,000.00 dollars. This opportunity is open for full and open competition under NAICS code 541380 and is not set aside for small businesses. Award will be based on the best value to the government, with technical factors outweighing cost in the evaluation process. Interested offerors must be actively registered in the System for Award Management and provide their Unique Entity Identifier, Taxpayer Identification Number, and business size certification. Responses must be submitted electronically to the designated point of contact by September 28, 2026, at 9:00am EST, and must include detailed pricing, delivery timeframes, and a completed copy of FAR 52.212-3.